查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1507174

癌症免疫治療市場、佔有率、規模、趨勢、行業分析報告：依類型、依應用、依最終用戶、依地區、依細分市場、預測，2024-2032年

Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report, By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application; By End-User; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，預計到2032年，全球癌症免疫治療市場規模將達到2,646.3億美元。本研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

由於癌症盛行率不斷上升、新療法的療效和精確度不斷提高、標靶療法的採用不斷增加以及新藥開發的研究和開發活動不斷增加，癌症免疫療法市場不斷成長。根據 NCT 註冊中心截至2020年 9月 8 日的資料，全球有超過 1,000 項使用免疫療法治療癌症的臨床試驗進行，處於不同的開發階段。隨著這些治療方法的開發取得進展，如果臨床試驗繼續產生積極的結果，可以期待新的有效的癌症免疫療法的出現。

癌症免疫療法的研發在發展中國家面臨重大挑戰，由於成本高昂，很難獲得足夠的治療經費。進行創新研究需要大量投入，這也是一個大問題。癌症免疫療法的高成本阻礙了大公司進入這個市場，獲利前景仍不確定。這些因素阻礙了癌症免疫治療市場的成長。

免疫學的進步在癌症免疫治療市場的成長和擴張中發揮著非常重要的作用。免疫學是研究免疫系統及其對各種疾病的反應的學科，近年來取得了長足的進步。這些進展使人們更了解癌細胞和免疫系統之間複雜的相互作用，為開發創新免疫療法鋪平了道路，徹底改變癌症治療。對免疫學的日益深入的了解也促進了學術界、製藥公司和研究機構之間的合作。這些合作加快癌症免疫治療領域的藥物開發和臨床試驗的步伐。科學家、臨床醫生和行業領導者的共同努力創造了一系列強大的新型免疫療法，為各種癌症類型的患者帶來了希望。

癌症免疫治療市場報告亮點

2023年，單株抗體因其針對癌細胞或免疫細胞上特定分子的特殊能力而在全球市場中獲得了很大佔有率。這種有針對性的方法使免疫系統能夠更有效地識別和對抗癌症，使單株抗體成為全球市場的主導區隔。

由於醫療保健支出不斷增加，世界各地醫院和診所免疫治療藥物的使用增加，預計醫院行業在幾年內將以顯著的年複合成長率成長。

北美在全球市場中佔有壓倒性的佔有率，但這是因為該地區的患者更容易獲得先進的癌症免疫治療，並且有知名公司進入該市場，這是由於政府機構和非機構的大量投資。

目錄

第1章 簡介

第2章 執行摘要

第3章 研究方法

第4章 全球癌症免疫治療市場洞察

  • 最終用戶快照
  • 癌症免疫治療市場動態
    • 推動因素和機會
      • 癌症患者的發生率不斷增加
      • 免疫學的進展
    • 抑制因素和挑戰
      • 治療費用高昂
  • 波特五力分析
  • PESTEL 分析
  • 癌症免疫治療市場的最終用戶趨勢
  • 價值鏈分析
  • 新冠肺炎（COVID-19）影響分析

第5章 全球癌症免疫治療市場：依類型

  • 主要發現
  • 簡介
  • 單株抗體
  • 癌症疫苗
  • 檢查點抑制劑和免疫調節劑

第6章 全球癌症免疫治療市場：依用途

  • 主要發現
  • 簡介
  • 肺癌
  • 乳癌
  • 大腸癌
  • 惡性黑色素瘤
  • 攝護腺癌
  • 頭頸癌
  • 其他

第7章 全球癌症免疫治療市場：依最終用戶

  • 主要發現
  • 簡介
  • 醫院
  • 診所
  • 癌症研究中心

第8章 全球癌症免疫治療市場：地區

  • 主要發現
  • 簡介
    • 癌症免疫治療市場評估：地區，2019-2032
  • 北美
    • 北美：依形態，2019-2032年
    • 北美：依最終使用者，2019-2032年
    • 北美：依用途，2019-2032年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲：依類型，2019-2032年
    • 歐洲：依最終使用者，2019-2032年
    • 歐洲：依用途，2019-2032年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
  • 亞太地區
    • 亞太地區：依類型，2019-2032年
    • 亞太地區：依最終使用者，2019-2032年
    • 亞太地區：依用途，2019-2032年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
  • 中東、非洲
    • 中東、非洲：依類型，2019-2032年
    • 中東和非洲：依最終用戶，2019-2032年
    • 中東和非洲：依用途，2019-2032年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
  • 拉丁美洲
    • 拉丁美洲：依類型，2019-2032年
    • 拉丁美洲：依最終使用者，2019-2032年
    • 拉丁美洲：依用途，2019-2032年
    • 墨西哥
    • 巴西
    • 阿根廷

第9章 競爭態勢

  • 擴張與收購分析
    • 擴張
    • 收購
  • 夥伴關係/協作/協定/揭露

第10章 公司簡介

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer AG
  • Bristol Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Novartis AG
  • OSE Immunotherapeutics
Product Code: PM1652

The global cancer immunotherapy market size is expected to reach USD 264.63 Billion by 2032, according to a new study by Polaris Market Research. The report "Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report, By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application; By End-User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The cancer immunotherapy market is growing due to the increasing incidence of cancer, the expanding effectiveness and accuracy of newer therapies, the rising adoption of target therapy, and increasing R&D activities for new drug development. Over 1,000 clinical trials for treating cancer with immune-based therapies are currently underway worldwide in various phases of development, as per the NCT Registry as of September 8, 2020. With the ongoing development of these therapies, players can expect the emergence of new and effective immunotherapies for cancer, provided trials continue to yield positive results.

The research and development of cancer immunotherapy is faced with a significant challenge in developing countries due to its high cost, making it difficult for treatment to receive adequate funding. Substantial investment is required for implementing innovative research, which is also a major concern. Due to the high cost of cancer immunotherapy, major companies are hesitant to enter this market, and their profitability prospects remain uncertain. These factors collectively hinder the growth of the cancer immunotherapy market.

Advances in immunology have played a pivotal role in driving the growth and expansion of the cancer Immunotherapy market. Immunology, the study of the immune system and its response to various diseases, has witnessed significant breakthroughs in recent years. These advancements have led to a deeper understanding of the complex interactions between cancer cells and the immune system, paving the way for the development of innovative immunotherapies that are revolutionizing cancer treatment. The growing understanding of immunology has also fostered collaboration between academia, pharmaceutical companies, and research institutions. These collaborations have accelerated the pace of drug development and clinical trials in the field of cancer Immunotherapy. The collective efforts of scientists, clinicians, and industry leaders have resulted in a robust pipeline of novel immunotherapies, offering hope to patients with various cancer types.

Cancer Immunotherapy Market Report Highlights

In 2023, monoclonal antibodies gained a significant share in the global market due to their specialized ability to target specific molecules on either cancer cells or immune cells. This targeted approach facilitated the immune system's recognition and combat of cancer more effectively, making monoclonal antibodies the dominant segment in the global market.

The hospital segment is anticipated to grow with a significant CAGR in the forecasted years owing to increased healthcare expenditures, which have led to a rise in the use of Immunotherapy drugs in hospitals and clinics worldwide.

In the global market, North America dominated the market due to the increased accessibility of advanced cancer immunotherapies for patients in the region, the presence of notable market players, and the substantial investments made by both governmental and non-governmental organizations in cancer immunotherapy research and development.

The global key market players include Amgen Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, OSE Immunotherapeutics, etc.

Polaris Market Research has segmented the cancer immunotherapy market report based on type, application, end-user, and region:

Cancer Immunotherapy, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Check Point Inhibitors & Immunomodulators

Cancer Immunotherapy, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others

Cancer Immunotherapy, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Clinics
  • Cancer Research Centers

Cancer Immunotherapy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Austria
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cancer Immunotherapy Market Insights

  • 4.1. Cancer Immunotherapy Market - End-User Snapshot
  • 4.2. Cancer Immunotherapy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of cancer patients
      • 4.2.1.2. Advances in immunology
      • 4.2.1.3. Restraints and Challenges
      • 4.2.1.4. High Treatment Cost
    • 4.2.2. Porter's Five Forces Analysis
    • 4.2.3. Bargaining Power of Suppliers (Moderate)
    • 4.2.4. Threats of New Entrants: (Low)
    • 4.2.5. Bargaining Power of Buyers (Moderate)
    • 4.2.6. Threat of Substitute (Moderate)
    • 4.2.7. Rivalry among existing firms (High)
  • 4.3. PESTEL Analysis
  • 4.4. Cancer Immunotherapy Market End-User Trends
  • 4.5. Value Chain Analysis
  • 4.6. COVID-19 Impact Analysis

5. Global Cancer Immunotherapy Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Monoclonal Antibodies
    • 5.3.1. Global Cancer Immunotherapy Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
  • 5.4. Cancer Vaccines
    • 5.4.1. Global Cancer Immunotherapy Market, by Cancer Vaccines, by Region, 2019-2032 (USD Billion)
  • 5.5. Check Point Inhibitors & Immunomodulators
    • 5.5.1. Global Cancer Immunotherapy Market, by Check Point Inhibitors & Immunomodulators, by Region, 2019-2032 (USD Billion)

6. Global Cancer Immunotherapy Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Lung Cancer
    • 6.3.1. Global Cancer Immunotherapy Market, by Lung Cancer, by Region, 2019-2032 (USD Billion)
  • 6.4. Breast Cancer
    • 6.4.1. Global Cancer Immunotherapy Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
  • 6.5. Colorectal Cancer
    • 6.5.1. Global Cancer Immunotherapy Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
  • 6.6. Melanoma
    • 6.6.1. Global Cancer Immunotherapy Market, by Melanoma, by Region, 2019-2032 (USD Billion)
  • 6.7. Prostate Cancer
    • 6.7.1. Global Cancer Immunotherapy Market, by Prostate Cancer, by Region, 2019-2032 (USD Billion)
  • 6.8. Head & Neck Cancer
    • 6.8.1. Global Cancer Immunotherapy Market, by Head & Neck Cancer, by Region, 2019-2032 (USD Billion)
  • 6.9. Others
    • 6.9.1. Global Cancer Immunotherapy Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Cancer Immunotherapy Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Cancer Immunotherapy Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.4. Clinics
    • 7.4.1. Global Cancer Immunotherapy Market, by Clinics, By Region, 2019-2032 (USD Billion)
  • 7.5. Cancer Research Centers
    • 7.5.1. Global Cancer Immunotherapy Market, by Cancer Research Centers, By Region, 2019-2032 (USD Billion)

8. Global Cancer Immunotherapy Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Cancer Immunotherapy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Cancer Immunotherapy Market - North America
    • 8.3.1. North America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.3.3. North America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Cancer Immunotherapy Market - U.S.
      • 8.3.4.1. U.S.: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Cancer Immunotherapy Market - Canada
      • 8.3.5.1. Canada: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Cancer Immunotherapy Market - Europe
    • 8.4.1. Europe: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Cancer Immunotherapy Market - UK
      • 8.4.4.1. UK: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Cancer Immunotherapy Market - France
      • 8.4.5.1. France: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Cancer Immunotherapy Market - Germany
      • 8.4.6.1. Germany: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Cancer Immunotherapy Market - Italy
      • 8.4.7.1. Italy: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Cancer Immunotherapy Market - Spain
      • 8.4.8.1. Spain: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Cancer Immunotherapy Market - Netherlands
      • 8.4.9.1. Netherlands: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Cancer Immunotherapy Market - Russia
      • 8.4.10.1. Russia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Cancer Immunotherapy Market - Asia Pacific
    • 8.5.1. Asia Pacific: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Cancer Immunotherapy Market - China
      • 8.5.4.1. China: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Cancer Immunotherapy Market - India
      • 8.5.5.1. India: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Cancer Immunotherapy Market - Malaysia
      • 8.5.6.1. Malaysia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Cancer Immunotherapy Market - Japan
      • 8.5.7.1. Japan: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Cancer Immunotherapy Market - Indonesia
      • 8.5.8.1. Indonesia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Cancer Immunotherapy Market - South Korea
      • 8.5.9.1. South Korea: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Cancer Immunotherapy Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Cancer Immunotherapy Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Cancer Immunotherapy Market - UAE
      • 8.6.5.1. UAE: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Cancer Immunotherapy Market - Israel
      • 8.6.6.1. Israel: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Cancer Immunotherapy Market - South Africa
      • 8.6.7.1. South Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Cancer Immunotherapy Market - Latin America
    • 8.7.1. Latin America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Cancer Immunotherapy Market - Mexico
      • 8.7.4.1. Mexico: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Cancer Immunotherapy Market - Brazil
      • 8.7.5.1. Brazil: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Cancer Immunotherapy Market - Argentina
      • 8.7.6.1. Argentina: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Amgen Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Astellas Pharma Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. AstraZeneca
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bayer AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bristol Myers Squibb
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Eli Lilly
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann-La Roche Ltd
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Merck KGaA
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Novartis AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. OSE Immunotherapeutics
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 4 Cancer Immunotherapy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 8 U.S.: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 11 Canada: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 14 Europe: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 UK: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 20 France: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 23 Germany: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 26 Italy: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 Spain: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 35 Russia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 China: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 44 India: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 50 Japan: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 56 South Korea: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 UAE: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 68 Israel: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 71 South Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 74 Latin America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 Mexico: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 80 Brazil: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 83 Argentina: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Cancer Immunotherapy Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Cancer Immunotherapy Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Cancer Immunotherapy Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End-User
  • Figure 11. Global Cancer Immunotherapy Market, by End-User, 2022 & 2032 (USD Billion)
  • Figure 12. Cancer Immunotherapy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Cancer Immunotherapy Market